Cancer drugs

Question 1

Antimetabolite mechanism

Answer 1

Inhibit DNA synthesis in S phase

Question 2

Topoisomerase inhibitor mechanism

Answer 2

Inhibits DNA synthesis and repair in S and G2 phase

Question 3

DNA damaging drug mechanism

Answer 3

Inhibit DNA repair in G2 phase

Question 4

Microtubule inhibitor mechanism

Answer 4

Interfere with mitotic spindle in M phase

Question 5

4 Classes of Antimetabolites

Answer 5

1) Purine analogs
2) Pyrimidine analogs
3) Folic acid analogs
4) Ribonucleoside reductase inhibitors

Question 6

Purine analogs (3)

Answer 6

CladribINE
AzathioprINE
6MP

Question 7

Pyramidine analogs (2)

Answer 7

CytarabINE

5-FU

Question 8

Folic Acid analog

Answer 8

MTX

Question 9

Ribonucleoside reductase inhibitor

Answer 9

Hydroxyurea

Question 10

2 Classes of topoisomerase inhibitor

Answer 10

Topoisomerase I inhibitors

Topoisomerase II inhibitors

Question 11

Topoisomerase I inhibitors (2)

Answer 11

irinOTECAN

topOTECAN

Question 12

Topoisomerase II inhibitors (2)

Answer 12

etoPOSIDE

teniPOSIDE

Question 13

Agents causing DNA damage w/free radicals (3)

Answer 13

bleomyCIN
doxoRUBICIN
daunoRUBICIN

Question 14

2 classes of microtubule inhibitors

Answer 14

Hyperstabilizers

Tubulin polymerization inhibitors

Question 15

Microtubule hyperstabilizers (2)

Answer 15

PacliTAXEL

other TAXOLs

Question 16

Tubulin polymerization inhibitors (2)

Answer 16

VINcriSTINE

VINblaSTINE

Question 17

2 Classes of DNA crosslinking agents

Answer 17

Platinum agents

Alkylating agents

Question 18

Platinum agents (2)

Answer 18

cisPLATIN

carboPLATIN

Question 19

Alkylating agents (4)

Answer 19

Bisulfan
Ifosfamide
Nitrosoureas (carMUSTINE)
Cyclophosphamide

Question 20

2 Classes of growth factor antagonists

Answer 20

VEGF inhibition

EGFR inhibition

Question 21

VEGF inhibitor

Answer 21

BeVacizumab

Question 22

EGFR inhibitors (2)

Answer 22

Cetixumab

Erlotinib

Question 23

2 Classes of estrogen receptor inhibitors

Answer 23

SERMs

HER-2 mabs

Question 24

SERMS

Answer 24

tamOXIFEN

ralOXIFENe

Question 25

HER-2 mab

Answer 25

trastuzumab

Question 26

2 Classes of growth signaling in hibitors

Answer 26

BRAF inhibitors | BCR-ABL/c-kit inhibitors

Question 27

BRAF inhibitor

Answer 27

vemuRAFenib

Question 28

BCR-ABL/c-kit inhibitor

Answer 28

imatinib

Question 29

Ototoxicity

Answer 29

Cisplatin/Carboplatin

Question 30

Peripheral neuropathy

Answer 30

Vincristine

Question 31

Pulmonary fibrosis

Answer 31

Bleomycin, busulfan

Question 32

Cardiotoxicity

Answer 32

Doxorubicin, trastuzumab

Question 33

Nephrotoxicity

Answer 33

Cisplatin, carboplatin

Question 34

hemorrhagic cystitis

Answer 34

Cyclophosphamide

Question 35

Myelosuppression

Answer 35

5-FU, 6-MP, MTX

Question 36

Leucovorin

Answer 36

Rescue for folate deficiency (myelosuppression) in MTX | Enhances action of 5-FU

Question 37

6-MP and Azathioprine: enhanced toxicity with

Answer 37

allopurinol or febuxostat (xanthine oxidase inhibitors)

Question 38

Platinum agents: prevent toxicity with

Answer 38

amifostine (free radical scavenger) and saline diuresis

Question 39

Doxorubicin and daunorubicin: prevent toxicity with

Answer 39

Dexrazoxane (iron chelation)

Question 40

Cyclophosphamide and ifosfamide: prevent toxicity with

Answer 40

mesna or N-acetylcysteine (bind toxic metabolites)

Question 41

Major adverse effect of tamoxifen

Answer 41

Endometrial cancer--partial agonist (no risk with raloxifene)

Question 42

Major adverse effect in SERMs

Answer 42

thromboembolism

Question 43

Tx CML with

Answer 43

imatinib (BCR/ABL)

Question 44

Treat PV with

Answer 44

Hydroxyurea

Question 45

Tx APL with

Answer 45

ATRA

Question 46

Tx hairy cell leukemia with

Answer 46

cladribine, pentostatin

Question 47

Tx follicular lymphoma with

Answer 47

rituximab